<?xml version='1.0' encoding='utf-8'?>
<document id="11185675"><sentence text="Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin."><entity charOffset="0-13" id="DDI-PubMed.11185675.s1.e0" text="Rosiglitazone" /><entity charOffset="67-74" id="DDI-PubMed.11185675.s1.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.11185675.s1.e0" e2="DDI-PubMed.11185675.s1.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s1.e0" e2="DDI-PubMed.11185675.s1.e1" /></sentence><sentence text="Rosiglitazone is a potent insulin-sensitizing oral hypoglycemic agent of the thiazolidinedione class that works through activation of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) nuclear receptor and improves glycemic control in patients with non-insulin-dependent diabetes mellitus"><entity charOffset="0-13" id="DDI-PubMed.11185675.s2.e0" text="Rosiglitazone" /><entity charOffset="77-94" id="DDI-PubMed.11185675.s2.e1" text="thiazolidinedione" /><pair ddi="false" e1="DDI-PubMed.11185675.s2.e0" e2="DDI-PubMed.11185675.s2.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s2.e0" e2="DDI-PubMed.11185675.s2.e1" /></sentence><sentence text=" The potential for a drug-drug interaction with oral digoxin was investigated"><entity charOffset="53-60" id="DDI-PubMed.11185675.s3.e0" text="digoxin" /></sentence><sentence text=" Subjects received both of the study regimens in a random sequence: digoxin 0"><entity charOffset="68-75" id="DDI-PubMed.11185675.s4.e0" text="digoxin" /></sentence><sentence text="375 mg plus matching placebo for rosiglitazone orally each morning for 14 days or digoxin 0"><entity charOffset="33-46" id="DDI-PubMed.11185675.s5.e0" text="rosiglitazone" /><entity charOffset="82-89" id="DDI-PubMed.11185675.s5.e1" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.11185675.s5.e0" e2="DDI-PubMed.11185675.s5.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s5.e0" e2="DDI-PubMed.11185675.s5.e1" /></sentence><sentence text="375 mg plus 8 mg rosiglitazone orally each morning for 14 days"><entity charOffset="17-30" id="DDI-PubMed.11185675.s6.e0" text="rosiglitazone" /></sentence><sentence text=" There was a 14-day washout period between sessions" /><sentence text=" Blood and urine were collected over 24 hours beginning on the morning of day 14 for measurement of digoxin concentrations"><entity charOffset="100-107" id="DDI-PubMed.11185675.s8.e0" text="digoxin" /></sentence><sentence text=" An equivalence statistical approach was used, with rosiglitazone considered to have no effect on the pharmacokinetics of digoxin if the 90% confidence interval (CI) for the ratio of digoxin plus rosiglitazone relative to digoxin plus placebo was completely contained within the range (0"><entity charOffset="52-65" id="DDI-PubMed.11185675.s9.e0" text="rosiglitazone" /><entity charOffset="122-129" id="DDI-PubMed.11185675.s9.e1" text="digoxin" /><entity charOffset="183-190" id="DDI-PubMed.11185675.s9.e2" text="digoxin" /><entity charOffset="196-209" id="DDI-PubMed.11185675.s9.e3" text="rosiglitazone" /><entity charOffset="222-229" id="DDI-PubMed.11185675.s9.e4" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e0" e2="DDI-PubMed.11185675.s9.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e0" e2="DDI-PubMed.11185675.s9.e1" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e0" e2="DDI-PubMed.11185675.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e0" e2="DDI-PubMed.11185675.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e0" e2="DDI-PubMed.11185675.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e1" e2="DDI-PubMed.11185675.s9.e1" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e1" e2="DDI-PubMed.11185675.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e1" e2="DDI-PubMed.11185675.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e1" e2="DDI-PubMed.11185675.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e2" e2="DDI-PubMed.11185675.s9.e2" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e2" e2="DDI-PubMed.11185675.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e2" e2="DDI-PubMed.11185675.s9.e4" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e3" e2="DDI-PubMed.11185675.s9.e3" /><pair ddi="false" e1="DDI-PubMed.11185675.s9.e3" e2="DDI-PubMed.11185675.s9.e4" /></sentence><sentence text="80, 1" /><sentence text="25) for the primary end points, AUC(0-24), and C24" /><sentence text=" Digoxin AUC(0-24) and C24 values were similar for digoxin 0"><entity charOffset="51-58" id="DDI-PubMed.11185675.s12.e0" text="digoxin" /></sentence><sentence text="375 mg plus matching placebo (18" /><sentence text="5 ng" /><sentence text="h/mL and 0" /><sentence text="579 ng/mL, respectively) and digoxin 0"><entity charOffset="29-36" id="DDI-PubMed.11185675.s16.e0" text="digoxin" /></sentence><sentence text="375 mg plus rosiglitazone (19"><entity charOffset="12-25" id="DDI-PubMed.11185675.s17.e0" text="rosiglitazone" /></sentence><sentence text="1 ng" /><sentence text="h/mL and 0" /><sentence text="594 ng/mL, respectively)" /><sentence text=" Point estimates were 1" /><sentence text="05 (90% CI: 1" /><sentence text="01, 1" /><sentence text="10) for AUC(0-24) and 1" /><sentence text="04 (90% CI: 0" /><sentence text="98, 1" /><sentence text="11) for C24" /><sentence text=" Oral and renal clearance were also similar between regimens" /><sentence text=" Digoxin alone or in combination with rosiglitazone was safe and well tolerated"><entity charOffset="1-8" id="DDI-PubMed.11185675.s29.e0" text="Digoxin" /><entity charOffset="38-51" id="DDI-PubMed.11185675.s29.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.11185675.s29.e0" e2="DDI-PubMed.11185675.s29.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s29.e0" e2="DDI-PubMed.11185675.s29.e1" /></sentence><sentence text=" The most common adverse experience was headache" /><sentence text=" Coadministration of digoxin with rosiglitazone had no significant effect on the safety or steady-state pharmacokinetics of digoxin"><entity charOffset="21-28" id="DDI-PubMed.11185675.s31.e0" text="digoxin" /><entity charOffset="34-47" id="DDI-PubMed.11185675.s31.e1" text="rosiglitazone" /><entity charOffset="124-131" id="DDI-PubMed.11185675.s31.e2" text="digoxin" /><pair ddi="false" e1="DDI-PubMed.11185675.s31.e0" e2="DDI-PubMed.11185675.s31.e0" /><pair ddi="false" e1="DDI-PubMed.11185675.s31.e0" e2="DDI-PubMed.11185675.s31.e1" /><pair ddi="false" e1="DDI-PubMed.11185675.s31.e0" e2="DDI-PubMed.11185675.s31.e2" /><pair ddi="false" e1="DDI-PubMed.11185675.s31.e1" e2="DDI-PubMed.11185675.s31.e1" /><pair ddi="false" e1="DDI-PubMed.11185675.s31.e1" e2="DDI-PubMed.11185675.s31.e2" /></sentence><sentence text="" /></document>